← All Skinvisible, INC filings

Skinvisible, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OQB
SKVI
Skinvisible, INC
8-K: Skinvisible Reports Licensee Quoin Pharmaceuticals Sees Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals announces significant achievements through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment, potentially leading to the first FDA approval for a formulation using Skinvisible's Invisicare delivery technology.
OQB
SKVI
Skinvisible, INC
8-K: Skinvisible Announces Promising Transdermal Obesity Formulation Results
Skinvisible's proprietary Invisicare technology demonstrates significant transdermal delivery of glucose-controlling agents, potentially revolutionizing obesity treatment.
OQB
SKVI
Skinvisible, INC
8-K: Skinvisible Inc. Issues 350,000 Units in Private Placement
Skinvisible Inc. has issued 350,000 units to accredited investors in a private placement, each unit consisting of one share of common stock and a warrant.
OQB
SKVI
Skinvisible, INC
8-K: Skinvisible Files Patent for Transdermal Obesity Drug Delivery System
Skinvisible has filed a provisional patent application for a transdermal drug delivery system using its Invisicare technology for obesity treatments.